von Deimling, Andreas

Glioblastoma: pathology, molecular mechanisms and markers

Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica

Glioma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 735

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Baumert, B. G., Hegi, M. E., van den Bent, M. J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., Brandes, A. A., Kantor, G., Taphoorn, M. J. B., Hassel, M. B., et al. (2016) · The Lancet Oncology

Glioma Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 495

IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO

Reuss, D. E., Mamatjan, Y., Schrimpf, D., Capper, D., Hovestadt, V., Kratz, A., Sahm, F., Koelsche, C., Korshunov, A., Olar, A., et al. (2015) · Acta Neuropathologica

Glioma Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 348

Yes and PI3K Bind CD95 to Signal Invasion of Glioblastoma

Kleber, S., Sancho-Martinez, I., Wiestler, B., Beisel, A., Gieffers, C., Hill, O., Thiemann, M., Mueller, W., Sykora, J., Kuhn, A., et al. (2008) · Cancer Cell

Glioma Diagnosis and TreatmentProtease and Inhibitor Mechanisms

Cited by 309

A highly conserved processed PTEN pseudogene is located on chromosome band 9p21

Dahia, P. L., FitzGerald, M. G., Zhang, X., Marsh, D. J., Zheng, Z., Pietsch, T., von Deimling, A., Haluska, F. G., Haber, D. A., & Eng, C. (1998) · Oncogene

PI3K/AKT/mTOR signaling in cancerProtein Tyrosine Phosphatases

Cited by 99

Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy

Peng, T., Ma, X., Hua, W., Wang, C., Chu, Y., Sun, M., Fermi, V., Hamelmann, S., Lindner, K., Shao, C., et al. (2025) · Cell Stem Cell

Glioma Diagnosis and TreatmentCancer Cells and Metastasis

Cited by 86

Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib

Berberich, A., Kessler, T., Thomé, C. M., Pusch, S., Hielscher, T., Sahm, F., Oezen, I., Schmitt, L.-M., Ciprut, S., Hucke, N., et al. (2019) · Clinical Cancer Research

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 75

Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity

Baumgarten, P., Harter, P. N., Tönjes, M., Capper, D., Blank, A. ‐., Sahm, F., von Deimling, A., Kolluru, V., Schwamb, B., Rabenhorst, U., et al. (2014) · Neuropathology and Applied Neurobiology

Glioma Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 53